Managing Toxicities of Targeted Therapies
October 16, 2026 – October 16, 2027
This activity is jointly provided by Global Education Group (Global) and GO2 for Lung Cancer.
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
The primary audience for this project is multidisciplinary healthcare professionals (HCPs) involved in the diagnosis, treatment, and longitudinal care of patients with advanced mNSCLC, including those with HER2 (ERBB2)-mutations. This includes medical oncologists, nurse practitioners, physician assistants, oncology pharmacists, molecular pathologists, oncology nurses and navigators, and other team members integral to diagnosis, biomarker testing, treatment selection, and toxicity management, especially those practicing in community, under-resourced, and rural settings, where disparities in access to biomarker testing and targeted therapies remain most pronounced.
This activity reviews the toxicity profiles associated with standard and HER2-targeted therapies, with particular emphasis on tyrosine kinase inhibitors and the gastrointestinal, cardiac, and hepatic adverse events commonly encountered in clinical practice. Through practical, evidence-based guidance, faculty discuss proactive patient education, monitoring, and supportive care strategies designed to prevent or mitigate toxicities, reduce unnecessary treatment interruptions, and optimize patient outcomes.
After completing this activity, the participant should be better able to:
Kathryn Mileham, MD
Atrium Health Levine Cancer Institute
Associate Professor, Cancer Medicine (Charlotte)
Wake Forest University School of Medicine
Christopher Pallas, MD
Atrium Health Levine Cancer Institute
Associate Professor, Cancer Medicine (Charlotte)
Wake Forest University School of Medicine
1-hour online activity
In support of improving patient care, this activity has been planned and implemented by Global Education Group and GO2 for Lung Cancer. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Education Group designates this continuing education activity for 1.0 contact hour(s) including 0.0 pharmacotherapeutic contact hour(s).
Disclosures of Relevant Financial Relationships Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by Joint Accreditation and all other accrediting bodies, as applicable, stating those activities where CE credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited CE program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are appropriately identified as relevant by Global. All relevant financial relationships have been mitigated in advance of delivery of the activity to learners.
For information about the Joint Accreditation (ACCME, ANCC) of this activity, please contact Global at 303-395-1782 or [email protected].
